FDA grants fast review of AZ's Brilinta to prevent recurring...

The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce the chances of patients having recurring stro

AZ claims FDA okay for Brilinta in coronary artery disease p...

AstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first heart attack or stroke in high-risk patients with coronary a

FDA approves new heart failure use for AZ's Farxiga

The FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in adults with reduced ejection fract

AstraZeneca on expanding its diabetes research franchise

AstraZeneca is hoping to build a strong focus on cardiovascular, renal, and metabolic (CVRM) diseases.

Amarin hit hard as generics loom for fish oil drug Vascepa

Novartis plots cardio trial in UK as London HQ opens

Novartis has announced the beginnings of a major cardiovascular outcomes trial in the UK, as it opened a new headquarters in London.